As life sciences organizations prepare for 2027, year-end quality reviews offer an opportunity to evaluate how well their systems are working. Deviations, corrective and preventive actions (CAPAs), audit findings, complaints, and supplier performance data can help reveal where controls are effective and where weaknesses continue to create risk.
The value of that review depends on what happens next. A comprehensive report provides limited benefit if the same issues carry into the new year without clear ownership, resources, or measures of improvement.
By connecting review findings to specific decisions, organizations can build a quality plan that addresses recurring problems and supports more reliable operations.
Connect Quality Data to Operational Risk
A useful review starts with more than a count of completed activities. Closing investigations, completing training, and meeting audit schedules provide information about execution, but those measures alone do not establish whether underlying problems have been resolved.
For example, a high CAPA closure rate may appear encouraging. If similar deviations continue across multiple departments, however, the organization should examine whether root cause investigations and effectiveness checks are addressing the conditions behind those events.
Review teams should consider:
- Which issues repeated after corrective actions were implemented?
- Where did investigations, approvals, or escalations consistently stall?
- Did complaints, deviations, and audit findings point to related weaknesses?
- Were improvements sustained across shifts, departments, and sites?
For pharmaceutical manufacturers, this evaluation also has a regulatory foundation. Under 21 CFR 211.180(e), required records must support at least annual evaluation of each drug product’s quality standards to determine whether specifications, manufacturing procedures, or control procedures need to change. That product-specific evaluation can inform broader planning, although it serves a distinct purpose from an organization-wide management review.
Look for Patterns Across Quality Systems
Reviewing each quality process separately can make shared problems harder to recognize.
An overdue supplier assessment, a recurring incoming material deviation, and a production interruption may have a common cause. Similarly, repeated documentation errors could reflect unclear procedures, workflow design, or competing responsibilities.
Bringing these findings together helps teams identify where a single improvement could address several sources of risk.
Consider an organization that repeatedly assigns retraining after batch record errors. A broader review might reveal that the errors cluster around one confusing instruction or a poorly designed form. Revising that process, with appropriate change control and effectiveness evaluation, may produce a more lasting improvement.
The goal is to understand why issues persist and which controls need to change.
Select Priorities That Reflect Risk
Year-end reviews often produce more improvement opportunities than an organization can complete at once. A practical 2027 plan should explain how priorities were selected.
Consider potential patient and product impact, recurrence, the strength of existing controls, and the consequences of delaying action. Resource availability should inform implementation planning, while significant risks receive appropriate escalation and interim controls.
ICH Q10 describes a pharmaceutical quality system model that connects monitoring, CAPA, change management, and management review to continual improvement. It also identifies resource allocation and improvements to processes and the quality system as potential outcomes of management review.
Using those principles, leadership can translate a long list of findings into a focused set of priorities with a clear rationale.
Define What Improvement Will Look Like
Broad objectives such as “strengthen CAPA” or “improve supplier oversight” need enough detail to guide execution.
Each priority should identify the problem being addressed, an accountable owner, required resources, milestones, and evidence that will demonstrate effectiveness.
For example, a CAPA improvement initiative might focus on recurring deviations associated with a specific process. The plan could include reviewing investigation quality, revising relevant controls, and evaluating recurrence over a justified monitoring period.
Measures should also account for workload and exposure. A decline in deviation counts may reflect lower production volume rather than stronger controls. Pairing activity measures with outcomes helps teams interpret progress more accurately.
Keep the Plan Active Throughout the Year
A quality plan should remain part of routine management discussion after January.
Establish a review cadence that allows teams to assess progress, address barriers, and respond to new information. Escalation criteria should make clear when missed milestones, ineffective actions, or emerging risks require leadership decisions.
Cross-functional participation is equally important. Operations, engineering, laboratory, supply chain, and other process owners need to understand their responsibilities and have the capacity to carry them out.
A useful test for the year-end review is whether the organization can explain what it will do differently in 2027, why those actions matter, and how it will know they worked.
The strength of a year-end quality review is ultimately measured by the decisions it drives. As organizations prepare for 2027, each significant finding should lead to a clear response: action to address the risk, accountability for implementation, and evidence that the improvement is working. When leadership connects those decisions to the resources and oversight needed to sustain them, the review becomes a foundation for stronger quality systems and more consistent protection of patients and product quality.
EMMA International supports life sciences organizations in evaluating quality systems and translating findings into practical improvement plans. Contact our team to discuss your organization’s quality priorities for 2027.




